These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 39216477)

  • 21. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
    Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
    Matsui Y; Yamada T; Katayama Y; Hirai S; Sawada R; Tachibana Y; Ishida M; Kawachi H; Nakamura R; Nishioka N; Morimoto K; Iwasaku M; Horinaka M; Sakai T; Tokuda S; Takayama K
    Cancer Sci; 2024 Oct; 115(10):3333-3345. PubMed ID: 39039802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF; Shen WZ; Jin X; Ren P; Zhang J
    Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.
    Theard PL; Linke AJ; Sealover NE; Daley BR; Yang J; Cox K; Kortum RL
    Mol Oncol; 2024 Mar; 18(3):641-661. PubMed ID: 38073064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L3MBTL1, a polycomb protein, promotes Osimertinib acquired resistance through epigenetic regulation of DNA damage response in lung adenocarcinoma.
    Zhang Z; Li Y; Shi R; Jia C; Xu S; Zhu G; Cao P; Huang H; Li X; Zhang H; Liu M; Chen C; Liu H; Kang C; Chen J
    Cell Death Dis; 2024 Sep; 15(9):649. PubMed ID: 39231972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
    Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
    Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
    EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.
    Grazini U; Markovets A; Ireland L; O'Neill D; Phillips B; Xu M; Pfeifer M; Vaclova T; Martin MJ; Bigot L; Friboulet L; Hartmaier R; Cuomo ME; Barry ST; Smith PD; Floc'h N
    Clin Cancer Res; 2024 Sep; 30(18):4143-4154. PubMed ID: 38630555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
    Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
    Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
    Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.
    Chen Z; Vallega KA; Boda VK; Quan Z; Wang D; Fan S; Wang Q; Ramalingam SS; Li W; Sun SY
    Adv Sci (Weinh); 2024 Sep; 11(35):e2310126. PubMed ID: 39044361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
    Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C
    Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Landscape of Acquired Resistance to Osimertinib in
    Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
    Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
    Marrocco I; Giri S; Simoni-Nieves A; Gupta N; Rudnitsky A; Haga Y; Romaniello D; Sekar A; Zerbib M; Oren R; Lindzen M; Fard D; Tsutsumi Y; Lauriola M; Tamagnone L; Yarden Y
    Cell Rep Med; 2023 Aug; 4(8):101142. PubMed ID: 37557179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
    La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
    J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.